Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of Single Dose NVP With 4 or 7 Day Course of Combivir for pMTCT - Treatment Options Preservation Study (TOPS)
This study has been completed.
Study NCT00144183   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on September 2, 2005.   Last Updated on May 18, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acquired Immunodeficiency Syndrome
Additional conditions recognized in this trial
HIV Infections
Immunologic Deficiency Syndromes
More general conditions related to this trial
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Nevirapine (NVP)
Zidovudine (ZCV)
3TC
Additional drug interventions recognized in this trial
Lamivudine, zidovudine drug combination
Nevirapine
Zidovudine
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antimetabolites
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services